A Comprehensive Monograph on Dipyridamole (DB00975)

Executive Summary

Dipyridamole is a pyrimidopyrimidine-derived small molecule with a long-standing and evolving role in cardiovascular medicine. Classified primarily as an antiplatelet agent, it possesses a unique dual mechanism of action that distinguishes it from other drugs in its class, involving both the inhibition of phosphodiesterase (PDE) enzymes and the blockade of cellular adenosine reuptake.[1] This multifaceted pharmacology underpins its diverse clinical applications and ongoing investigational potential.

The core clinical utility of dipyridamole is well-defined by several key regulatory approvals. It is indicated as an adjunctive therapy to warfarin for the prophylaxis of thromboembolism following cardiac valve replacement surgery. In combination with low-dose aspirin as the extended-release product Aggrenox, it is a cornerstone for the secondary prevention of ischemic stroke and transient ischemic attacks (TIAs). Furthermore, its potent vasodilatory properties are harnessed in its intravenous formulation, which serves as a pharmacological stress agent for myocardial perfusion imaging in patients unable to undergo exercise-based testing.[3]

The therapeutic effects of dipyridamole are derived from its ability to increase intracellular levels of the second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and to elevate extracellular concentrations of adenosine. These actions collectively inhibit platelet aggregation and induce significant vasodilation.[6] This vasodilatory property, while crucial for its diagnostic use, is also the source of its most common side effects, including headache and dizziness, and gives rise to the clinically significant "coronary steal" phenomenon in patients with advanced coronary artery disease.[3]

The safety profile of dipyridamole is well-characterized. Common adverse effects are generally manageable and include headache, dizziness, and gastrointestinal upset. More significant safety considerations involve an increased risk of bleeding, particularly when combined with other antithrombotic agents, and the potential for exacerbation of angina in patients with severe underlying coronary disease.[4]

Despite being considered a legacy medication, dipyridamole is the subject of considerable contemporary research. Preclinical studies suggest a powerful synergistic cardioprotective effect when combined with statins, a potential that was not explored in the older trials that led to its diminished role in coronary artery disease management. Its pleiotropic anti-inflammatory, anti-viral, and anti-cancer properties are being actively investigated for therapeutic repurposing in a range of conditions, including COVID-19, HIV, and various malignancies.[9] The future of dipyridamole may therefore lie not in direct competition with newer, more targeted antiplatelet agents, but in the strategic exploitation of its unique multi-modal mechanism in niche applications and synergistic combination therapies.

Chemical Identity and Physicochemical Properties

A thorough understanding of the chemical and physical properties of dipyridamole is fundamental to appreciating its formulation, bioavailability, and biological activity.

Chemical Classification

Dipyridamole is a complex heterocyclic small molecule. Chemically, it is classified as a pyrimidopyrimidine derivative, characterized by a fused two-ring system at its core. Its full chemical name is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8.[12] The structure also contains four hydroxyl groups, classifying it as a tetrol, and two piperidine rings. The presence of multiple nitrogen atoms within its structure makes it a tertiary amino compound. This intricate molecular architecture, featuring numerous hydrogen bond donors (four hydroxyl groups) and acceptors (twelve nitrogen and oxygen atoms), is directly responsible for its physicochemical properties and its ability to interact with multiple biological targets.[13]

Physical Description

In its solid state, dipyridamole presents as an intensely yellow, odorless crystalline powder or as needles.[14] A critical handling property is its sensitivity to light, which necessitates storage in cool, dark conditions to prevent degradation.[16]

Solubility Profile

Dipyridamole exhibits a distinct and clinically significant pH-dependent solubility profile. It is readily soluble in acidic media, such as dilute acids, but is only slightly soluble in water at neutral pH.[13] Its solubility in organic solvents varies; it is soluble in chloroform, methanol, and ethanol but very slightly soluble in acetone and ethyl acetate.[15]

The requirement of an acidic environment for dissolution is a pivotal factor governing the drug's oral absorption and clinical performance. Solid oral dosage forms, such as immediate-release tablets, must dissolve in the acidic milieu of the stomach to be absorbed effectively in the gastrointestinal tract.[18] This physicochemical characteristic underlies a significant drug-drug interaction; the co-administration of common gastric acid-suppressing agents, including proton pump inhibitors (PPIs) and H2-receptor antagonists, raises gastric pH, thereby inhibiting the dissolution and subsequent absorption of standard dipyridamole tablets and liquid formulations.[1] This can result in highly variable and potentially sub-therapeutic plasma concentrations, posing a risk of treatment failure, particularly in the critical setting of secondary stroke prevention. This very challenge was a primary driver for the development of advanced formulations, such as the extended-release pellets contained within the Aggrenox capsule, which were engineered to provide more reliable absorption independent of gastric pH.[18]

Hazard Information

For laboratory and manufacturing purposes, dipyridamole is classified as a hazardous substance. According to safety data sheets, it is designated as causing skin irritation (H315), serious eye irritation (H319), and causing damage to organs (H370). Consequently, handling of the pure substance requires appropriate personal protective equipment and adherence to safety protocols, such as avoiding dust inhalation (P260) and ensuring thorough washing after handling (P264).[16]

Table 2.1: Physicochemical and Structural Properties of Dipyridamole

Property	Value	Source(s)
Identifiers
Common Name	Dipyridamole	1
DrugBank ID	DB00975	12
CAS Number	58-32-2	12
IUPAC Name	2-[[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol	13
InChI	InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2	13
InChIKey	IZEKFCXSFNUWAM-UHFFFAOYSA-N	13
SMILES	C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO	12
UNII	64ALC7F90C	12
ChEBI ID	CHEBI:4653	12
PubChem CID	3108	12
Formula & Weight
Molecular Formula	C24​H40​N8​O4​	13
Molecular Weight	504.6 g/mol	13
Experimental Properties
Physical State	Solid, yellow crystalline powder	13
Melting Point	163 – 168 °C	13
Solubility (Water)	Slightly soluble; 9.22e-01 g/L	13
LogP	1.5	13
Computed Properties
Topological Polar Surface Area	145 A˚2	13
Hydrogen Bond Donor Count	4	13
Hydrogen Bond Acceptor Count	12	13
Rotatable Bond Count	12	13

Molecular Pharmacology and Mechanism of Action

The pharmacological profile of dipyridamole is uniquely complex, arising from its interaction with multiple biological pathways. While its mechanism of action is not fully elucidated, it is understood to be multifaceted, a characteristic that defines both its therapeutic effects and its side effect profile.[20] Its actions are primarily attributed to a dual mechanism involving the modulation of adenosine signaling and the inhibition of cyclic nucleotide degradation.

Dual Primary Mechanisms

Dipyridamole’s pharmacologic effects stem from two main molecular actions that work in concert.

Inhibition of Adenosine Reuptake

A cornerstone of dipyridamole's action is its dose-dependent inhibition of the equilibrative nucleoside transporter 1 (ENT1).[7] This transporter is ubiquitously expressed on the cell membranes of erythrocytes, platelets, and vascular endothelial cells, where it facilitates the rapid uptake of endogenous adenosine from the extracellular space.[1] By blocking ENT1, dipyridamole effectively prevents this uptake, leading to a significant elevation in the local extracellular concentration of adenosine, a potent endogenous signaling molecule.[7]

Inhibition of Phosphodiesterase (PDE)

Dipyridamole also functions as an inhibitor of several phosphodiesterase (PDE) isoenzymes, the enzymes responsible for hydrolyzing and thus inactivating the second messengers cAMP and cGMP.[1] While its inhibitory effect on

cAMP-specific PDE is considered relatively weak, it demonstrates more potent inhibition of cGMP-specific PDEs (such as PDE5) and other isoforms including PDE3, PDE8A, and PDE8B.[1] This inhibition leads to the intracellular accumulation of both

cAMP and cGMP, amplifying their downstream signaling effects.

Downstream Pharmacodynamic Effects

The combination of these two primary mechanisms produces a cascade of downstream effects, most notably on platelets and vascular smooth muscle.

Antiplatelet Action

The antithrombotic effect of dipyridamole is a direct and synergistic consequence of its dual actions. The elevated extracellular adenosine resulting from ENT1 blockade stimulates A2-type adenosine receptors on the platelet surface. This receptor activation triggers adenylate cyclase, the enzyme that synthesizes intracellular cAMP.[7] Simultaneously, dipyridamole's inhibition of PDE enzymes prevents the rapid degradation of this newly formed

cAMP.[1] The resulting high intracellular concentration of

cAMP is a powerful inhibitor of platelet function, blocking platelet activation, aggregation, and adhesion in response to various physiological stimuli such as adenosine diphosphate (ADP) and collagen.[1]

Vasodilation

Dipyridamole is a potent vasodilator, with a particularly pronounced effect on the coronary circulation. This effect is also multi-faceted. The increased local concentration of adenosine directly acts on its receptors on vascular smooth muscle cells, causing relaxation and vasodilation.[7] Furthermore, the inhibition of

cGMP-specific PDE potentiates the vasodilatory actions of endothelium-derived nitric oxide (NO), which exerts its effects through the cGMP signaling pathway.[5] Finally, there is evidence that dipyridamole may also directly stimulate endothelial cells to release prostacyclin (

PGI2​), which is itself a potent vasodilator and inhibitor of platelet aggregation.[2]

This pleiotropic, multi-target mechanism contrasts sharply with the highly specific, single-receptor focus of many modern drugs, such as the P2Y12 inhibitors. This "blunt instrument" approach, targeting two interconnected physiological systems, explains both the broad spectrum of dipyridamole's effects and its potential for repurposing in complex diseases where multiple pathways are dysregulated, such as cancer, fibrosis, and viral infections.[10] At the same time, this lack of specificity is responsible for its characteristic side effects, like headache and flushing, which are direct results of systemic vasodilation.

While it was once hypothesized that dipyridamole's vasodilatory effect was significantly mediated by potentiation of the NO/cGMP pathway, human studies have clarified this point. A key study using forearm blood flow measurements demonstrated that dipyridamole significantly potentiated vasodilation induced by an infusion of adenosine. However, it did not alter the vasodilatory response to acetylcholine (which is NO-dependent) or to nitroprusside (an NO donor that acts directly on the cGMP pathway).[21] The magnitude of the adenosine-induced vasodilation showed a strong positive correlation with plasma dipyridamole concentrations, a relationship that was absent for the NO-pathway vasodilators. This provides compelling evidence that in peripheral resistance vessels, the drug's primary vasodilatory action is mediated through the potentiation of endogenous adenosine, not a significant enhancement of NO signaling. This finding helps explain why the drug's effects are so effectively and rapidly reversed by adenosine receptor antagonists like aminophylline and caffeine.[1]

The "Coronary Steal" Phenomenon

A critical pharmacodynamic consequence of dipyridamole's potent, non-selective coronary vasodilation is the "coronary steal" phenomenon. This effect is the basis for its diagnostic utility but also represents a major clinical risk.[8] In patients with significant coronary artery disease (CAD), some vessels are narrowed by atherosclerotic plaques. The smaller arterioles distal to these stenoses are often already maximally dilated at rest to maintain blood flow to the heart muscle. When intravenous dipyridamole is administered, it causes profound dilation of the healthy, non-stenosed coronary arteries and arterioles.[27] This shunts a disproportionate amount of blood flow down these low-resistance pathways, effectively "stealing" blood from the ischemic areas supplied by the stenosed arteries, where the vessels cannot dilate further. This redistribution of blood flow can precipitate or worsen myocardial ischemia, leading to symptoms of chest pain and characteristic changes on an electrocardiogram (ECG).[8]

This iatrogenic induction of ischemia is precisely why intravenous dipyridamole is used as a pharmacological alternative to exercise in conjunction with thallium-201 myocardial perfusion imaging. The test reveals areas of the heart that become ischemic under pharmacological stress, identifying regions supplied by stenosed coronary arteries.[1] Conversely, this same phenomenon means that dipyridamole is contraindicated in patients with unstable angina or a recently sustained myocardial infarction and must be used with extreme caution in any patient with known severe underlying CAD.[3]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of dipyridamole dictates its dosing schedule, explains inter-patient variability, and informs the management of drug interactions. Its journey through the body—absorption, distribution, metabolism, and excretion (ADME)—is characterized by variable absorption and extensive hepatic metabolism.

Absorption

• Bioavailability and Rate: Following oral administration, dipyridamole is readily but variably absorbed from the gastrointestinal tract. The oral bioavailability is reported to be in the range of 37% to 66%, indicating that a significant portion of the dose may not reach systemic circulation.[1] For immediate-release tablets, the average time to reach peak plasma concentration (Tmax) is approximately 75 minutes.[15]
• pH-Dependent Absorption: As previously noted, the absorption of dipyridamole is critically dependent on gastric pH. An acidic environment is necessary to dissolve the drug from its solid form, a prerequisite for absorption. This makes its bioavailability susceptible to alteration by food or concurrent medications that raise gastric pH, such as PPIs.[1]
• Food Effect: To ensure the most consistent absorption, it is recommended that dipyridamole be taken on an empty stomach, either at least one hour before or two hours after meals, with a full glass of water. However, to mitigate potential gastrointestinal upset, clinicians may advise patients to take it with food or milk.[29]

Distribution

• Protein Binding: Once in the bloodstream, dipyridamole is highly bound to plasma proteins, with binding percentages ranging from 91% to 99%.[15] It primarily binds to alpha-1-acid glycoprotein.[27] This extensive protein binding limits the amount of free, pharmacologically active drug in circulation and means that dipyridamole is not likely to be effectively removed by dialysis in the event of an overdose.[1]
• Volume of Distribution: Dipyridamole has a large apparent volume of distribution (Vd​), estimated at 2 to 3 L/kg.[31] This indicates that the drug distributes extensively into tissues outside of the plasma compartment.

Metabolism

• Site and Pathway: Dipyridamole undergoes extensive metabolism, which occurs primarily in the liver.[2] The main metabolic pathway is phase II conjugation with glucuronic acid, forming a monoglucuronide metabolite.[2] This metabolite is also pharmacologically active, though to a lesser extent than the parent compound.

Elimination

• Route of Excretion: The primary route of elimination for dipyridamole and its metabolites is via the bile, with subsequent excretion in the feces. Renal excretion of the drug is negligible.[1]
• Half-Life: The decline in plasma concentration of dipyridamole follows a multi-compartment model. After oral administration, the plasma concentration profile is best described by a biexponential model, with an initial, rapid distribution phase (alpha half-life) of approximately 40 minutes, followed by a slower terminal elimination phase (beta half-life) of about 10 to 12 hours.[1] Following intravenous administration, a tri-exponential decline is observed, with half-lives averaging 3-12 minutes, 33-62 minutes, and a terminal phase of 11.6-15 hours.[27]
• Special Populations: Due to the negligible renal excretion, no specific dose adjustments are necessary for patients with renal impairment.[3] However, given that the liver is the primary site of metabolism and elimination, caution is advised when administering dipyridamole to patients with severe hepatic impairment.[3]

The pharmacokinetic profile of dipyridamole has had a direct and significant impact on its clinical use and pharmaceutical development. The combination of a relatively short initial half-life and a terminal half-life of around 10 hours necessitates a frequent dosing schedule for the immediate-release formulation to maintain steady, therapeutic plasma concentrations required for continuous antiplatelet effect. The standard regimen is typically four times a day.[3] Such a frequent dosing schedule can be a major obstacle to patient adherence, which is of paramount importance in long-term secondary stroke prevention. This clinical challenge was the direct impetus for the development of Aggrenox, a fixed-dose combination product containing low-dose aspirin and an extended-release (ER) formulation of dipyridamole. The ER component was specifically designed to slow the drug's absorption, allowing for a more convenient twice-daily dosing regimen, thereby improving the likelihood of patient compliance.[4] This evolution from an immediate-release to an extended-release formulation is a classic example of how understanding a drug's ADME profile can drive pharmaceutical innovation to overcome clinical limitations.

Clinical Applications and Dosing Regimens

Dipyridamole has carved out specific niches in clinical practice, with its use defined by several FDA-approved indications as well as a growing number of off-label and investigational applications.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved dipyridamole for three distinct clinical uses:

• Thromboembolism Prophylaxis in Prosthetic Heart Valve Replacement: Dipyridamole tablets are indicated as an adjunctive therapy to be used with coumarin anticoagulants, such as warfarin, for the prevention of postoperative thromboembolic complications in patients who have undergone cardiac valve replacement surgery.[3] This indication is supported by randomized controlled trials demonstrating that the combination of dipyridamole and warfarin decreased the incidence of such events by 62% to 91% compared to warfarin treatment alone.[15]
• Secondary Prevention of Ischemic Stroke: The fixed-dose combination product containing 200 mg of extended-release dipyridamole and 25 mg of aspirin (brand name Aggrenox) is FDA-approved to reduce the risk of stroke in patients who have previously experienced a transient ischemic attack (TIA) or a completed thrombotic ischemic stroke.[1] It is important to note that dipyridamole as a monotherapy is not licensed for this indication.[1]
• Myocardial Perfusion Imaging (Pharmacological Stress Test): The intravenous formulation of dipyridamole is indicated as an alternative to exercise for thallium-201 myocardial perfusion imaging. This diagnostic test is used for the evaluation of coronary artery disease in patients who are unable to perform adequate physical exercise.[3]

Off-Label and Investigational Uses

Beyond its approved indications, dipyridamole has been explored for a wide array of other conditions, reflecting its pleiotropic mechanisms of action.

• Cardiovascular Conditions: It has been used off-label for the treatment of peripheral arterial disease (PVD) and to lower pulmonary hypertension.[1] More recent emerging evidence suggests potential therapeutic benefits in select patients with heart failure and microvascular angina, although these uses are not yet standard practice.[9]
• Restless Legs Syndrome (RLS): Dipyridamole is conditionally recommended by the American Academy of Sleep Medicine as a second-line experimental agent for the treatment of RLS, though it is noted that this recommendation is based on a low certainty of evidence.[1]
• Ophthalmology: The drug is being investigated in Phase 2 clinical trials for the topical treatment of Dry Eye Syndrome and Pterygium.[35]
• Oncology (Drug Repurposing): There is a growing body of preclinical and early clinical research investigating dipyridamole as an anti-cancer agent. The rationale is based on its ability to inhibit platelet activity, which is known to facilitate tumor growth and metastasis, and on its potential to interfere with tumor metabolism. Studies have suggested potential efficacy in breast cancer (including triple-negative breast cancer), colorectal cancer, pancreatic cancer, and melanoma.[10]
• Infectious and Inflammatory Diseases:
• COVID-19: During the pandemic, dipyridamole was investigated in multiple clinical trials (e.g., TOLD, DICER) for its potential combination of anti-inflammatory, antithrombotic, and direct anti-viral effects against the SARS-CoV-2 virus.[9]
• HIV: A proof-of-concept study demonstrated that dipyridamole could reduce T-cell activation in virally suppressed individuals with HIV, suggesting a potential role in mitigating the chronic inflammation associated with the disease.[11]

Table 5.1: Dipyridamole Formulations, Strengths, and Dosing by Indication

Indication	Formulation	Strength(s)	Population	Dosing Regimen	Source(s)
Thromboembolism Prophylaxis (Post-Valve Replacement)	Oral Tablet	25 mg, 50 mg, 75 mg	Adult	75-100 mg PO four times daily, as an adjunct to warfarin.	3
Secondary Stroke Prevention	Oral Extended-Release Capsule (in combination with Aspirin)	200 mg Dipyridamole / 25 mg Aspirin (Aggrenox)	Adult	One capsule PO twice daily.	4
Myocardial Perfusion Imaging (Stress Test)	Injectable Solution	5 mg/mL	Adult	0.142 mg/kg/min IV infusion over 4 minutes. Maximum total dose typically 60-70 mg.	3
Antiplatelet Effect (Off-label)	Oral Tablet	25 mg, 50 mg, 75 mg	Pediatric (>12 years)	2.0 to 6.0 mg/kg/day PO in divided doses. Data are limited; not a first-line agent.	3
General Use	Oral Tablet (short-acting)	25 mg, 50 mg, 75 mg	Geriatric	Avoid use per Beers Criteria due to risk of orthostatic hypotension. More effective alternatives are available. (IV form for stress testing is acceptable).	3

Safety Profile, Tolerability, and Risk Management

The safety profile of dipyridamole is well-established through decades of clinical use and numerous trials. While generally tolerated, it is associated with a distinct set of adverse effects, contraindications, and drug interactions that require careful clinical management.

Adverse Effects

The adverse effects of dipyridamole are largely predictable based on its vasodilatory and antiplatelet properties.

• Common Adverse Events: The most frequently reported side effects, particularly with the oral combination product Aggrenox as seen in the ESPS2 trial, include [4]:
• Headache: The most common adverse event, occurring in approximately 28% of patients.[4] It is often dose-limiting, especially upon treatment initiation. A common mitigation strategy is to begin with one capsule at bedtime along with low-dose aspirin in the morning for the first week before resuming the twice-daily regimen.[4]
• Dizziness: Reported in about 12% of patients.[3]
• Gastrointestinal Disturbances: Dyspepsia (indigestion) is common (13%), along with stomach pain, diarrhea, and nausea.[4]
• Flushing: A sensation of warmth, related to vasodilation, is also frequently reported.[38]
• Serious Adverse Events:
• Cardiovascular: Dipyridamole's vasodilatory effects can lead to serious cardiovascular events. Exacerbation of angina is a significant concern, particularly with intravenous use (reported in 19.7% of patients in one study).[3] Other effects include hypotension and tachycardia.[4] While rare, fatal and non-fatal myocardial infarction have been reported with IV administration for stress testing (0.1% incidence).[28]
• Bleeding: As an antiplatelet agent, dipyridamole increases the risk of bleeding. This risk is amplified when used in combination with other anticoagulants or antiplatelet drugs. Post-procedural and operative hemorrhage have been reported.[22] Notably, the risk of intracranial hemorrhage with the Aggrenox combination product was found to be similar to that of aspirin monotherapy in the ESPS2 trial.[1]
• Hepatic Effects: Dipyridamole has been associated with elevated hepatic enzymes.[15] Although rare, post-marketing reports include cases of hepatitis and hepatic failure.[4]
• Hypersensitivity Reactions: Allergic reactions can occur and may include rash, urticaria, and angioedema. Severe bronchospasm is a rare but serious risk, particularly with the intravenous formulation (0.2% incidence in one large study).[4]

Contraindications, Warnings, and Precautions

Careful patient selection is crucial to minimize the risks associated with dipyridamole therapy.

• Contraindications: The primary contraindication is a known hypersensitivity to dipyridamole or any of the components in the formulation.[5]
• Warnings and Precautions:
• Coronary Artery Disease: Due to its potent vasodilatory effects and the risk of the coronary steal phenomenon, dipyridamole should be used with caution in patients with severe coronary artery disease, particularly those with unstable angina or a recent myocardial infarction.[3]
• Hypotension: The drug can cause or worsen hypotension and should be used cautiously in patients with pre-existing low blood pressure.[3]
• Bronchospastic Disease: The intravenous formulation should be used with caution in patients with bronchospastic diseases like asthma, as it can induce severe bronchospasm.[3]
• Myasthenia Gravis: Dipyridamole may counteract the therapeutic effect of cholinesterase inhibitors, which are used to treat myasthenia gravis. This can lead to a potential aggravation of the disease.[5]
• Hepatic and Renal Impairment: While no dose adjustment is needed for renal impairment, the drug should be used with caution in patients with severe hepatic impairment. The Aggrenox combination product should be avoided in patients with severe hepatic or renal insufficiency.[3]

Overdose Management

Experience with dipyridamole overdose is limited, but the expected symptoms are extensions of its pharmacologic effects.

• Symptoms: Overdose is likely to present with symptoms of excessive vasodilation, including a warm feeling, flushing, sweating, restlessness, a feeling of weakness, dizziness, and anginal complaints. A significant drop in blood pressure and reflex tachycardia may also be observed.[1]
• Treatment: Management is primarily symptomatic and supportive. Gastric lavage may be considered if the ingestion was recent. There is a specific antidote to reverse the vasodilatory effects: slow intravenous administration of aminophylline (50-250 mg) or caffeine, which act as adenosine receptor antagonists.[1] Because dipyridamole is highly protein-bound, hemodialysis is not likely to be an effective method of removal.[1]

Table 6.1: Clinically Significant Drug-Drug and Food Interactions of Dipyridamole

Interacting Agent(s)	Type of Interaction	Clinical Effect & Mechanism	Management Recommendation	Source(s)
Adenosinergic Agents (Adenosine, Regadenoson)	Pharmacodynamic (Synergism)	Potentiates cardiovascular effects (hypotension, bradycardia, heart block). Dipyridamole blocks adenosine's cellular reuptake, increasing its concentration and effect.	Dose adjustment of adenosine may be necessary. Interrupt oral dipyridamole/Aggrenox for 48 hours prior to pharmacological stress testing.	1
Anticoagulants & Antiplatelets (Warfarin, Aspirin, Clopidogrel)	Pharmacodynamic (Synergism)	Additive anti-hemostatic effects lead to an increased risk of bleeding.	Monitor closely for signs of bleeding (bruising, hematuria, melena). Triple therapy (aspirin, clopidogrel, dipyridamole) is associated with a significantly higher bleeding risk and is generally not recommended.	1
Cholinesterase Inhibitors (Neostigmine, Pyridostigmine)	Pharmacodynamic (Antagonism)	May counteract the anticholinesterase effect, potentially leading to an exacerbation of myasthenia gravis symptoms.	Use with caution. Monitor patients with myasthenia gravis for worsening muscle weakness.	5
Antihypertensives & Vasodilators	Pharmacodynamic (Synergism)	Additive vasodilatory effects can lead to an increased risk of hypotension.	Monitor blood pressure closely, especially upon treatment initiation or dose adjustment.	2
Methylxanthines (Caffeine, Theophylline)	Pharmacodynamic (Antagonism)	Competitively antagonizes adenosine receptors, thereby reversing the vasodilatory effect of dipyridamole.	For Cardiac Stress Testing: Patients must avoid all caffeine-containing products (coffee, tea, soda, chocolate) for at least 24 hours prior to the test to prevent a false-negative result. For Chronic Oral Use: This interaction is not considered clinically significant for the antiplatelet effect.	1
Gastric Acid Suppressors (PPIs, H2-Blockers)	Pharmacokinetic (Absorption)	Increases gastric pH, which inhibits the dissolution and absorption of immediate-release dipyridamole tablets and liquid.	For immediate-release formulations, separate administration by 2-3 hours from indigestion medicines. This interaction is not a significant concern for the extended-release capsules (Aggrenox).	1
P-gp/BCRP Transporter Modulators (e.g., afatinib, alpelisib)	Pharmacokinetic (Transport)	Dipyridamole can inhibit efflux transporters like P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), potentially increasing plasma concentrations of co-administered drugs that are substrates for these transporters.	Avoid co-administration when possible. If necessary, monitor closely for toxicity of the substrate drug and consider dose adjustments as per its prescribing information.	44

Historical Development and Evolution in Clinical Practice

The clinical journey of dipyridamole is a compelling narrative of pharmacological serendipity, therapeutic re-evaluation, and evolving scientific understanding. Its path from a failed angina treatment to a key agent in stroke prevention and a subject of modern repurposing research provides a valuable case study in drug development.

Discovery and Initial Development (1950s-1960s)

Dipyridamole was first synthesized and developed in the late 1950s by researchers at the German pharmaceutical company Dr. Karl Thomae GmbH, which would later become part of Boehringer Ingelheim.[18] It was introduced to the market in 1959 and was initially promoted, starting in 1961, as a coronary vasodilator for the treatment of angina pectoris.[9] The rationale was that by dilating coronary arteries, it would increase blood flow to the heart muscle. However, its clinical efficacy for preventing effort-induced angina was never conclusively established in trials, and it was soon discovered that its non-selective vasodilation could paradoxically induce ischemia via the "coronary steal" phenomenon. As a result, this original indication quickly fell out of favor.[47]

A Shift in Focus: The Rise of Antithrombotic Use (1960s-1980s)

The true therapeutic trajectory of dipyridamole began with a serendipitous discovery. In the mid-1960s, experimental studies began to uncover its inhibitory effects on platelet function.[47] This finding sparked an "explosion of interest" in its potential as an antithrombotic agent, an area of research that at the time was even more focused on dipyridamole than on aspirin.[47] This shift in focus led to its first major regulatory success in the United States in 1961, when the FDA approved it as an adjunctive therapy to coumarin anticoagulants for the prevention of thromboembolic complications following cardiac valve replacement—an indication that remains valid today.[49]

Throughout the 1970s and 1980s, researchers explored its potential in other cardiovascular areas. The Persantine-Aspirin Re-Infarction Study (PARIS) I and II trials, conducted in 1980 and 1986 respectively, investigated the combination of dipyridamole and aspirin for the secondary prevention of myocardial infarction. However, these trials yielded mixed and largely non-significant results, failing to demonstrate a clear benefit of the combination over aspirin alone in the coronary circulation setting.[9]

Consolidation and Refinement (1990s-2000s)

The 1990s marked a pivotal turning point for dipyridamole, solidifying its role in neurology. The landmark European Stroke Prevention Study-2 (ESPS2), a large, robustly designed trial, was published. It demonstrated unequivocally that a combination of low-dose aspirin and a new extended-release formulation of dipyridamole was significantly more effective than aspirin alone for the secondary prevention of stroke. Crucially, this superior efficacy was achieved without a significant increase in the risk of major bleeding.[4] This trial was fundamental to the FDA approval of the combination product, Aggrenox, and its adoption into clinical guidelines worldwide.

The findings of ESPS2 were later confirmed by the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), which further cemented the place of the combination therapy in stroke prevention guidelines.[9] A subsequent meta-analysis by the Antithrombotic Trialists' Collaboration in 2002 confirmed the stroke-specific benefits of the combination therapy.[9]

The Modern Era: An "Old" Drug with New Questions (2010s-Present)

In recent years, the role of dipyridamole has continued to evolve. Its use in the management of coronary artery disease has largely fallen out of practice, with modern guidelines favoring newer, more potent antiplatelet agents like P2Y12 inhibitors.[9] Enthusiasm for more intensive antiplatelet strategies involving dipyridamole was significantly tempered by the TARDIS trial in 2017. This trial showed that a triple therapy regimen of aspirin, clopidogrel, and dipyridamole was not more effective than standard dual therapy for acute stroke and caused a significantly higher rate of bleeding complications.[40]

Simultaneously, a renaissance of interest has emerged, focusing on the drug's other, less-explored pharmacological properties. Its "older," less-targeted mechanisms—including adenosine modulation, anti-inflammatory effects, and anti-proliferative actions—are now being actively investigated for repurposing in a host of complex diseases. This has led to numerous investigational trials in oncology, infectious diseases like COVID-19 and HIV, and inflammatory conditions, breathing new life into this decades-old compound.[9]

Analysis of Pivotal and Recent Clinical Trial Evidence

The evidence base for dipyridamole's clinical use is built upon several landmark trials, particularly in the field of stroke prevention, as well as a growing number of recent studies exploring its potential in new therapeutic areas. A critical analysis of this evidence is essential to understand its appropriate place in modern medicine.

Landmark Trials in Stroke Prevention

The role of dipyridamole in secondary stroke prevention is defined by two pivotal trials and subsequent meta-analyses.

• ESPS-2 (European Stroke Prevention Study-2): This was a large (n=6602), multicenter, double-blind, placebo-controlled trial with a 2x2 factorial design. It compared the efficacy of low-dose aspirin (25 mg twice daily), extended-release (ER) dipyridamole (200 mg twice daily), the combination of both, and placebo in patients with a prior ischemic stroke or TIA.[4] The key finding was that the combination of aspirin and ER-dipyridamole was superior to all other arms. It reduced the risk of stroke by 23% compared to aspirin alone and by 37% compared to placebo. Importantly, the rate of major bleeding events in the combination group was not significantly different from that in the aspirin-alone group.[4] This trial was instrumental in establishing the combination therapy as a standard of care.
• ESPRIT (European/Australian Stroke Prevention in Reversible Ischaemia Trial): This trial randomized patients with recent cerebral ischemia of presumed arterial origin to aspirin alone (30 to 325 mg daily) or aspirin plus dipyridamole (200 mg twice daily).[52] The results confirmed the findings of ESPS-2, showing that the combination therapy was more effective than aspirin monotherapy in reducing the composite primary outcome of vascular death, nonfatal stroke, nonfatal myocardial infarction, or major bleeding complication.[9] While the open-label design was a limitation, the outcome events were assessed by a blinded committee, strengthening the validity of the findings.
• Meta-Analyses: Subsequent systematic reviews and meta-analyses, including a notable Cochrane review, have consistently confirmed that dipyridamole, either alone or with aspirin, reduces the risk of stroke recurrence. These analyses affirm that the combination of aspirin and dipyridamole is more effective than aspirin alone for this specific outcome.[1]

Trials of Intensive Antiplatelet Therapy

The success of dual antiplatelet therapy led to the hypothesis that a more intensive, triple-therapy regimen might be even more effective. This was tested in the TARDIS trial.

• TARDIS (Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke): This was a large (n=3096), randomized, open-label, phase 3 superiority trial. It compared an intensive 30-day regimen of aspirin, clopidogrel, and dipyridamole against guideline-based therapy (either clopidogrel alone or the combination of aspirin and dipyridamole) in patients with acute non-cardioembolic ischemic stroke or TIA.[40] The trial was stopped early by the data monitoring committee due to safety concerns and futility. The results showed that the intensive triple therapy did not reduce the incidence or severity of recurrent stroke or TIA compared to standard therapy. In contrast, it significantly increased the risk of bleeding, including both major and minor hemorrhagic events.[40] TARDIS was a landmark negative trial that provided definitive evidence against the routine use of this intensive antiplatelet strategy.

Recent and Ongoing Investigational Trials

The current research landscape for dipyridamole is vibrant, focusing on repurposing the drug for non-traditional indications.

• COVID-19: Several phase 2 trials were rapidly initiated to evaluate dipyridamole's potential anti-viral, anti-inflammatory, and antithrombotic benefits. The TOLD trial (NCT04424901) was terminated early due to low enrollment as the pandemic evolved.[37] The DICER trial (NCT04391179) also explored its use.[9] An open-label pilot study of the Aggrenox combination (NCT04410328) found that while outcomes such as mortality and respiratory failure were numerically lower in the treatment group, the differences did not reach statistical significance.[36]
• Inflammation and Immunology: Two key proof-of-concept studies have provided promising results. A trial in virally suppressed individuals with HIV (NCT01894232) found that dipyridamole significantly decreased T-cell activation, supporting its potential as a systemic anti-inflammatory agent.[11] Another study in a human endotoxemia model (NCT01091571) showed that pretreatment with dipyridamole augmented the anti-inflammatory cytokine ( IL−10) response and accelerated the decline of pro-inflammatory cytokines following an inflammatory challenge.[56]
• Other Therapeutic Areas: Clinical trials have also explored the use of dipyridamole in schizophrenia (NCT00349973) [57], systemic sclerosis (NCT05559580) [58], and in combination with novel antiviral agents [59], highlighting its broad investigational appeal.

The clinical evidence for dipyridamole demonstrates that its therapeutic benefit is highly context-dependent. Its efficacy is clearly and robustly established when used in a specific combination (with low-dose aspirin) for a specific indication (secondary prevention of cerebrovascular ischemic events). This is the cornerstone of its modern clinical value.[4] However, attempts to extrapolate this success to other settings have largely failed. Trials in myocardial infarction prevention were disappointing, and the TARDIS trial showed that simply escalating antiplatelet intensity by adding a third agent was harmful.[9] This suggests that the benefit of dipyridamole is not due to a simple, universal antiplatelet effect. Instead, its specific mechanisms—perhaps related to its effects on cerebral vasodilation or a unique interaction with aspirin in the cerebrovascular bed—appear to be uniquely suited to the pathophysiology of ischemic stroke but less so for coronary thrombosis. This selective efficacy is a key, yet not fully understood, feature of the drug.[52]

Table 8.1: Summary of Major Clinical Trials for Dipyridamole

Trial Name	Year	Patient Population	Interventions	Primary Outcome	Key Finding/Clinical Impact
ESPS-2	1996	6,602 patients with prior ischemic stroke or TIA	Aspirin 25mg BID vs. ER-Dipyridamole 200mg BID vs. Combination vs. Placebo	Stroke	Combination therapy reduced stroke risk by 23% vs. aspirin alone and 37% vs. placebo, without increasing major bleeding. Established the combination as a standard of care.
ESPRIT	2006	2,739 patients with recent TIA or minor ischemic stroke	Aspirin (30-325mg/day) vs. Aspirin + Dipyridamole (200mg BID)	Composite of vascular death, nonfatal stroke, nonfatal MI, or major bleeding	Combination therapy was superior to aspirin alone in preventing the composite outcome. Confirmed the findings of ESPS-2.
TARDIS	2017	3,096 patients with acute non-cardioembolic ischemic stroke or TIA	Triple therapy (Aspirin + Clopidogrel + Dipyridamole) vs. Guideline therapy (Clopidogrel or Aspirin + Dipyridamole)	Incidence and severity of recurrent stroke or TIA at 90 days	Triple therapy did not improve efficacy but significantly increased the risk of bleeding. Provided strong evidence against this intensive strategy.

Table 8.2: Overview of Recent and Ongoing Investigational Trials (by Therapeutic Area)

Therapeutic Area	Trial Identifier	Phase	Intervention	Stated Goal
COVID-19	NCT04424901 (TOLD)	2	Dipyridamole vs. Placebo	To evaluate efficacy in treating respiratory and circulatory dysfunction in hospitalized patients. (Terminated early)
COVID-19	NCT04410328	Pilot	Aggrenox vs. Standard Care	To evaluate the effect of Aggrenox on clinical outcomes in patients with SARS-CoV-2. (No significant difference)
HIV Inflammation	NCT01894232	Proof-of-Concept	Dipyridamole vs. Placebo	To determine if dipyridamole decreases systemic inflammation and T-cell activation in virally suppressed HIV patients. (Positive)
Systemic Inflammation	NCT01091571	2	Dipyridamole vs. Placebo	To study the effects of dipyridamole on the inflammatory response during human experimental endotoxemia. (Positive)
Oncology	N/A	Preclinical	Dipyridamole	To investigate anti-tumor and anti-metastatic effects in various cancer models.
Schizophrenia	NCT00349973	2	Dipyridamole vs. Olanzapine	To assess the efficacy of dipyridamole on positive, negative, and cognitive symptoms of schizophrenia.
Ophthalmology	NCT02782260	2	Topical Dipyridamole	To assess efficacy in treating dry eye symptoms in subjects with pterygium.

Synthesis and Future Directions: The Role of an "Underestimated" Drug in Modern Medicine

Dipyridamole occupies a unique and somewhat paradoxical position in the modern pharmacopeia. It is simultaneously an "old" drug, whose use in some traditional areas like coronary artery disease has been largely superseded by newer agents, and a "promising" drug that is the subject of vigorous investigation for a host of novel applications.[9] Its clinical efficacy is definitively proven in a very specific context—secondary stroke prevention when combined with aspirin—but has been found lacking or even detrimental in others, such as high-intensity antiplatelet regimens.[40] This complex profile stems directly from its multifaceted mechanism of action, which is both its greatest strength, endowing it with pleiotropic effects, and its greatest weakness, contributing to a lack of target specificity and a notable side effect burden.

The Case for Re-evaluation in Cardiovascular Disease

A compelling argument can be made that the potential of dipyridamole in the management of coronary artery disease (CAD) was unfairly dismissed based on the results of outdated clinical trials.[9] These foundational studies were conducted in an era before the widespread use of statins and often employed high doses of aspirin, two factors that are now known to be critical confounders.

A key area of emerging science is the Statin Synergy Hypothesis. Preclinical animal models have demonstrated a powerful synergistic effect between dipyridamole and statins in limiting myocardial infarct size. The proposed mechanism is elegant: statins have been shown to increase the production of endogenous adenosine, while dipyridamole blocks its cellular reuptake. The combination thus creates a potent, localized surge in this cardioprotective nucleoside, an effect that was entirely absent and unmeasured in the older trials that now form the basis of negative guideline recommendations.[9] Furthermore, the high doses of aspirin used in many of those early trials may have attenuated the cardioprotective benefits of both statins and dipyridamole. This creates a strong scientific rationale for conducting new, well-designed clinical trials to re-evaluate dipyridamole in the modern context—specifically, in combination with statins and low-dose aspirin—for patients with CAD, heart failure, and microvascular angina.[9]

The Future of Dipyridamole: A Repurposing Story

The most exciting future for dipyridamole likely lies in drug repurposing, leveraging its unique mechanisms of action to address complex diseases far beyond its original indications.

• Oncology: The role of platelets in promoting tumor growth, angiogenesis, and metastasis is an area of intense research. By inhibiting platelet function, reducing platelet-driven inflammation, and potentially interfering directly with tumor cell metabolism, dipyridamole presents as a highly attractive candidate for adjunctive cancer therapy. Its known safety profile, oral bioavailability, and low cost make it an ideal agent for investigation in combination with standard chemotherapy or immunotherapy for a variety of solid tumors, including breast, colorectal, and pancreatic cancer.[10]
• Inflammation and Virology: Dipyridamole's ability to potently modulate the adenosine signaling pathway, which is a key regulator of inflammation, positions it as a potential therapy for diseases characterized by immune dysregulation. Its observed in-vitro anti-viral activity against several RNA viruses, combined with its systemic anti-inflammatory and antithrombotic effects, made it a logical candidate for investigation during the COVID-19 pandemic. This same rationale supports its exploration as an adjunctive therapy to dampen the chronic inflammation that persists in virally suppressed individuals with HIV.[11]
• Fibrosis: Early research has suggested that dipyridamole may possess anti-fibrotic properties. This has spurred the development of novel analogues with improved pharmacokinetic profiles specifically designed to treat conditions like idiopathic pulmonary fibrosis, demonstrating that the core chemical scaffold of dipyridamole continues to inspire new drug discovery efforts.[25]

Final Conclusion

Dipyridamole is far more than a simple antiplatelet agent. It is a pharmacologically complex, multi-modal drug whose full therapeutic potential may have been historically overlooked due to the context of its early clinical evaluation. While its established roles in secondary stroke prevention and cardiac stress testing are secure, its future will be defined by the intelligent exploration of its pleiotropic effects. Through well-designed modern trials investigating synergistic combinations, particularly with statins in cardiovascular disease, and through its repurposing for complex diseases like cancer, chronic inflammation, and fibrosis, this "underestimated vascular protective drug" [60] may yet find new and vital roles in the therapeutic armamentarium.

Works cited

1. Dipyridamole - Wikipedia, accessed August 11, 2025, https://en.wikipedia.org/wiki/Dipyridamole
2. Dipyridamole: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 11, 2025, https://go.drugbank.com/drugs/DB00975
3. Dipyridamole - StatPearls - NCBI Bookshelf, accessed August 11, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554455/
4. This label may not be the latest approved by FDA. For current ..., accessed August 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020884s040lbl.pdf
5. Persantine - accessdata.fda.gov, accessed August 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/012836s061lbl.pdf
6. Mechanism of action of dipyridamole - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/6356465/
7. What is the mechanism by which dipyridamole prevents adenosine reuptake? - Dr.Oracle, accessed August 11, 2025, https://www.droracle.ai/articles/52644/how-does-dipyridamole-prevent-adenosine-reuptake-what-is-the-mechanism
8. Dipyramidole pharmacology (1) | PPTX | Heart and Cardiovascular Diseases - SlideShare, accessed August 11, 2025, https://www.slideshare.net/slideshow/dipyramidole-pharmacology-1/250604083
9. Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era, accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8271326/
10. Repurposing Drugs as Expanding Cancer Treatment Palette: Dipyridamole as a Cancer Treatment | Integrative Holistic Cancer Therapy, Houston, Texas - Omega Precision Oncology, accessed August 11, 2025, https://i2b.us/repurposing-drugs-as-expanding-cancer-treatment-palette-dipyridamole-as-a-cancer-treatment/
11. Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus–Associated Chronic Inflammation | The Journal of Infectious Diseases | Oxford Academic, accessed August 11, 2025, https://academic.oup.com/jid/article/221/10/1598/5529471
12. Dipyridamole - PharmaKB, accessed August 11, 2025, https://www.pharmakb.com/drug-report/dipyridamole
13. Dipyridamole | C24H40N8O4 | CID 3108 - PubChem, accessed August 11, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dipyridamole
14. Dipyridamole – Knowledge and References - Taylor & Francis, accessed August 11, 2025, https://taylorandfrancis.com/knowledge/Engineering_and_technology/Chemical_engineering/Dipyridamole/
15. Dipyridamole: Package Insert / Prescribing Information - Drugs.com, accessed August 11, 2025, https://www.drugs.com/pro/dipyridamole.html
16. Dipyridamole 58-32-2 | Tokyo Chemical Industry UK Ltd., accessed August 11, 2025, https://www.tcichemicals.com/GB/en/p/D2274
17. Dipyridamole 58-32-2 | TCI AMERICA, accessed August 11, 2025, https://www.tcichemicals.com/US/en/p/D2274
18. US4427648A - Dipyridamole-containing pharmaceutical form - Google Patents, accessed August 11, 2025, https://patents.google.com/patent/US4427648A/en
19. Dipyridamole - brand name list from Drugs.com, accessed August 11, 2025, https://www.drugs.com/ingredient/dipyridamole.html
20. Dipyridamole - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 11, 2025, https://www.pediatriconcall.com/drugs/dipyridamole/502
21. Role of Adenosine and Nitric Oxide on the Mechanisms of Action of Dipyridamole | Stroke, accessed August 11, 2025, https://www.ahajournals.org/doi/10.1161/01.str.0000179044.37760.9d
22. Pytazen SR modified release tablet, 150 mg - Medsafe, accessed August 11, 2025, https://www.medsafe.govt.nz/profs/datasheet/p/pytazensrtab.pdf
23. Translational Therapeutics of Dipyridamole | Arteriosclerosis, Thrombosis, and Vascular Biology - American Heart Association Journals, accessed August 11, 2025, https://www.ahajournals.org/doi/10.1161/atvbaha.107.160226
24. Dipyridamole - CCC Pharmacology - LITFL, accessed August 11, 2025, https://litfl.com/dipyridamole/
25. Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis - PMC, accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9182104/
26. pmc.ncbi.nlm.nih.gov, accessed August 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7990686/#:~:text=Currently%2C%20dipyridamole%20(100%20mg%20given,patients%20(DICER%2C%20NCT04391179).](https://www.google.com/url?q=https://pmc.ncbi.nlm.nih.gov/articles/PMC7990686/%23:~:text%3DCurrently%252C%2520dipyridamole%2520(100%2520mg%2520given,patients%2520(DICER%252C%2520NCT04391179).&sa=D&source=editors&ust=1754905774200347&usg=AOvVaw1Br9649jQd0iLx20MBfU6P)
27. Dipyridamole Injection: Package Insert / Prescribing Info - Drugs.com, accessed August 11, 2025, https://www.drugs.com/pro/dipyridamole-injection.html
28. 74956 Dipridamole Approval - accessdata.fda.gov, accessed August 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/74956_Dipridamole.pdf
29. Dipyridamole (oral route, intravenous route) - Side effects & dosage - Mayo Clinic, accessed August 11, 2025, https://www.mayoclinic.org/drugs-supplements/dipyridamole-oral-route-intravenous-route/description/drg-20063475
30. Dipyridamole - HealthHub, accessed August 11, 2025, https://www.healthhub.sg/a-z/medications/dipyridamole
31. Dipyridamole | Drug Lookup | Pediatric Care Online - AAP Publications, accessed August 11, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5455/Dipyridamole
32. Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man - PMC, accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1386303/
33. Dipyridamole: Mechanism of Action, Side Effects, Drug Class & More - GoodRx, accessed August 11, 2025, https://www.goodrx.com/dipyridamole/what-is
34. Dipyridamole Uses, Side Effects & Warnings - Drugs.com, accessed August 11, 2025, https://www.drugs.com/mtm/dipyridamole.html
35. Dipyridamole Unknown Status Phase 2 Trials for Dry Eye Syndrome (DES) / Pterygium of Conjunctiva and Cornea Treatment - DrugBank, accessed August 11, 2025, https://go.drugbank.com/drugs/DB00975/clinical_trials?conditions=DBCOND0074986%2CDBCOND0083037&phase=2&purpose=treatment&status=unknown_status
36. A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection | PLOS One - Research journals, accessed August 11, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0274243
37. Study Details | Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19, accessed August 11, 2025, https://clinicaltrials.gov/study/NCT04424901
38. Dipyridamole: MedlinePlus Drug Information, accessed August 11, 2025, https://medlineplus.gov/druginfo/meds/a682830.html
39. Dipyridamole (Persantine): Uses & Side Effects - Cleveland Clinic, accessed August 11, 2025, https://my.clevelandclinic.org/health/drugs/18825-dipyridamole-tablets
40. (PDF) Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): A randomised, open-label, phase 3 superiority trial - ResearchGate, accessed August 11, 2025, https://www.researchgate.net/publication/321973421_Antiplatelet_therapy_with_aspirin_clopidogrel_and_dipyridamole_versus_clopidogrel_alone_or_aspirin_and_dipyridamole_in_patients_with_acute_cerebral_ischaemia_TARDIS_A_randomised_open-label_phase_3_sup
41. Dipyridamole and Alcohol/Food Interactions - Drugs.com, accessed August 11, 2025, https://www.drugs.com/food-interactions/dipyridamole.html
42. Dipyridamole Food, Alcohol, Supplements and Drug Interactions, accessed August 11, 2025, https://www.wellrx.com/dipyridamole/lifestyle-interactions/
43. Taking dipyridamole with other medicines and herbal supplements - NHS, accessed August 11, 2025, https://www.nhs.uk/medicines/dipyridamole/taking-dipyridamole-with-other-medicines-and-herbal-supplements/
44. Persantine, (dipyridamole) dosing, indications, interactions, adverse ..., accessed August 11, 2025, https://reference.medscape.com/drug/persantine-dipyridamole-342147
45. DIPYRIDAMOLE - New Drug Approvals, accessed August 11, 2025, https://newdrugapprovals.org/2022/01/18/dipyridamole/
46. Boehringer Ingelheim - Wikiwand, accessed August 11, 2025, https://www.wikiwand.com/en/articles/Boehringer_Ingelheim
47. Dipyridamole – Knowledge and References - Taylor & Francis, accessed August 11, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Dipyridamole/
48. Dipyridamole-echocardiography test: historical background and physiologic basis | European Heart Journal | Oxford Academic, accessed August 11, 2025, https://academic.oup.com/eurheartj/article-abstract/10/4/365/537555
49. Dipyridamole - LiverTox - NCBI Bookshelf, accessed August 11, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548123/
50. Timeline of major events and clinical trials pertaining to dipyrdidamole use in cardiovascular disease - ResearchGate, accessed August 11, 2025, https://www.researchgate.net/figure/Timeline-of-major-events-and-clinical-trials-pertaining-to-dipyrdidamole-use-in_fig2_353154842
51. Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events, accessed August 11, 2025, https://www.ahajournals.org/doi/10.1161/01.str.0000149621.95215.ea
52. Dipyridamole in Stroke Prevention - American Heart Association Journals, accessed August 11, 2025, https://www.ahajournals.org/doi/10.1161/01.str.0000090346.45784.c3
53. Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke - TARDIS, accessed August 11, 2025, https://www.acc.org/latest-in-cardiology/clinical-trials/2018/01/08/15/18/tardis
54. Study Details | Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19, accessed August 11, 2025, https://www.clinicaltrials.gov/study/NCT04424901
55. Study Details | Aggrenox To Treat Acute Covid-19 | ClinicalTrials.gov, accessed August 11, 2025, https://clinicaltrials.gov/study/NCT04410328
56. Dipyridamole augments the antiinflammatory response during human endotoxemia - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/22129171/
57. Study Details | Clinical Trial of Dipyridamole in Schizophrenia | ClinicalTrials.gov, accessed August 11, 2025, https://clinicaltrials.gov/study/NCT00349973
58. A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms | ClinicalTrials.gov, accessed August 11, 2025, https://www.clinicaltrials.gov/study/NCT05559580
59. Study Details | Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19 | ClinicalTrials.gov, accessed August 11, 2025, https://clinicaltrials.gov/study/NCT05166876
60. Dipyridamole, an underestimated vascular protective drug - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/16382298/